Annapurna Therapeutics, formerly AAVLife, announces today a name change and an expanded scope in their gene therapy portfolio. As noted in the release, Annapurna is focused on treating the cardiomyopathy associated with FA and their current efforts include detailed cardiac testing in individuals with FA to help determine the best measurements for safety and efficacy in future trials and doing the necessary work in pre-clinical animals. For information on the cardiomyopathy studies at Weill Cornell please click here.   FARA looks forward to continued collaboration and support for Annapurna's efforts to advance gene therapy treatments for FA.

Press Release: